8DXT

Fab arm of antibody GAR12 bound to the receptor binding domain of SARS-CoV-2.

8DXT の概要

• エントリーDOI: 10.2210/pdb8dxt/pdb
• 分子名称: Light chain of Fab arm of antibody GAR12, Heavy chain of Fab arm of antibody GAR12, Spike protein S1, ... (5 entities in total)
• 機能のキーワード: anti-cov-2, antibodies, convalescent patients, receptor binding domain., antiviral protein
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 71664.88

構造登録者

Langley, D.B.,Christ, D.,Henry, J.Y. (登録日: 2022-08-03, 公開日: 2023-01-18, 最終更新日: 2024-10-30)

主引用文献

Rouet, R.,Henry, J.Y.,Johansen, M.D.,Sobti, M.,Balachandran, H.,Langley, D.B.,Walker, G.J.,Lenthall, H.,Jackson, J.,Ubiparipovic, S.,Mazigi, O.,Schofield, P.,Burnett, D.L.,Brown, S.H.J.,Martinello, M.,Hudson, B.,Gilroy, N.,Post, J.J.,Kelleher, A.,Jack, H.M.,Goodnow, C.C.,Turville, S.G.,Rawlinson, W.D.,Bull, R.A.,Stewart, A.G.,Hansbro, P.M.,Christ, D.
Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients.
Nat Commun, 14:687-687, 2023

PubMed Abstract: Emerging variants of concern (VOCs) are threatening to limit the effectiveness of SARS-CoV-2 monoclonal antibodies and vaccines currently used in clinical practice; broadly neutralizing antibodies and strategies for their identification are therefore urgently required. Here we demonstrate that broadly neutralizing antibodies can be isolated from peripheral blood mononuclear cells of convalescent patients using SARS-CoV-2 receptor binding domains carrying epitope-specific mutations. This is exemplified by two human antibodies, GAR05, binding to epitope class 1, and GAR12, binding to a new epitope class 6 (located between class 3 and 5). Both antibodies broadly neutralize VOCs, exceeding the potency of the clinical monoclonal sotrovimab (S309) by orders of magnitude. They also provide prophylactic and therapeutic in vivo protection of female hACE2 mice against viral challenge. Our results indicate that exposure to SARS-CoV-2 induces antibodies that maintain broad neutralization against emerging VOCs using two unique strategies: either by targeting the divergent class 1 epitope in a manner resistant to VOCs (ACE2 mimicry, as illustrated by GAR05 and mAbs P2C-1F11/S2K14); or alternatively, by targeting rare and highly conserved epitopes, such as the new class 6 epitope identified here (as illustrated by GAR12). Our results provide guidance for next generation monoclonal antibody development and vaccine design.

PubMed: 36755042
DOI: 10.1038/s41467-023-36295-5

実験手法

X-RAY DIFFRACTION (2.25 Å)